Allergy/Asthma News

The FDA has approved the first generic of Proventil HFA metered-dose inhaler — albuterol sulfate — for treatment or prevention of bronchospasm in reversible obstructive airway disease and prevention of exercise-induced bronchospasm in patients aged at least 4 years, according a press release.

Adults prescribed glucocorticoid therapy are at a higher risk for developing serious complications from COVID-19, according to an editorial published in the Journal of Clinical Endocrinology & Metabolism. It was the top story in endocrinology last week.

With most of the population in the United States living in areas under stay-at-home orders, many individuals may be turning to comfort foods and feeling limited in the amount of physical activity they can do.

Hurricane Maria caused some residents of Puerto Rico to experience upper respiratory illness symptoms up to 1 year after the storm struck, according to study findings.

In the largest long-term peanut immunotherapy trial to date, the epicutaneous immunotherapy patch known as Viaskin Peanut increased patients’ protection over time from allergic reactions, according to researchers.

Mothers who experienced symptoms of depression near the end of their pregnancy were more likely to have children with lowered immunity than mothers without depressive symptoms, according to a study recently published in Clinical & Experimental Allergy.

Despite potential eligibility for no-cost medical treatment, patients with low socioeconomic status enrolled in the World Trade Center Health Registry experienced more ED visits due to asthma, according to a study published in JAMA Network Open.

The FDA issued an alert about EpiPen 0.3 mg auto-injectors, EpiPen Jr. 0.15 mg auto-injectors and authorized generic versions, stating that these products may have delayed or incorrect injections that could cause injury or death.

Although national guidelines recommend physical activity in people with asthma, few of these patients receive counseling from their health care providers, according to a study that was to be presented at the American Academy of Asthma, Allergy & Immunology Annual Meeting.

Omalizumab may effectively treat food allergy symptoms in patients with alpha-gal syndrome, according to research from a small study that was to be presented at the American Academy of Asthma, Allergy & Immunology Annual Meeting.